Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AI-Driven Opportunistic Screening and Risk-Adapted Management of Steatotic Liver Disease

NCT07613827 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT07613827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07613827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AI-Driven Opportunistic Screening and Risk-Adapted Management of Steatotic Liver Disease
Lead sponsor
Shengjing Hospital
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
February 24, 2026
Completion date
February 24, 2027
Enrollment
7,969 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver fibrosis, liver fibrosis progression in chronic liver disease, liver steatosis, steatotic liver disease, steatotic liver disease of mixed origin (metald)